US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.00

+0.79181.32%

Volume:26.38K

Turnover:1.60M

Market Cap:295.24M

PE:19.95

High:61.03

Open:60.28

Low:59.85

Close:60.21

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.80

T/O Rate:0.54%

Dividend:1.52

Dividend Rate:2.50%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health reports COSMOS study published in Cancer Research Communications

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer

Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer

THOMSON REUTERS

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288

THOMSON REUTERS

Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity

Simply Wall St.

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares

Guardant Health price target raised to $200 from $190 at Guggenheim

BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call

Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer

Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer

New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

Axsome Therapeutics, Inc. : Deutsche Bank Cuts Target Price to $267 from $280

THOMSON REUTERS

Shenzhen Lifotronic Technology Secures Medical Device Registration Certificate for Photon Therapeutic Apparatus

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares

Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says

MT Newswires Live

Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61,"timestamp":1791222279447,"preClose":60.2082,"halted":0,"volume":26376,"delay":0,"changeRate":0.013151032583601605,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Trading","change":0.7918,"latestTime":"10-05 13:45:27 EDT","open":60.28,"high":61.03,"low":59.85,"amount":1596163.237368,"amplitude":0.019599,"askPrice":61.11,"askSize":800,"bidPrice":61,"bidSize":2079,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791230400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.2082,"sharesOutstanding":2480000,"nav":59.60729,"aum":291451253.04,"dividendRate":0.024972,"bidAskSpread":0.001966,"preHourTrading":{"tag":"盘前","latestPrice":60.2082,"preClose":60.2082,"latestTime":"07:36 EDT","volume":16,"amount":963.658208,"timestamp":1791200176330,"change":0,"changeRate":0,"amplitude":0.000362},"postHourTrading":{"tag":"盘后","latestPrice":60.2,"preClose":60.2082,"latestTime":"19:30 EDT","volume":10,"amount":602.441,"timestamp":1790983804674,"change":-0.0082,"changeRate":-0.000136,"amplitude":0},"volumeRatio":0.80393,"impliedVol":0.1481,"impliedVolPercentile":0.7371},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.80393,"shares":4840000,"dividePrice":1.5233,"high":61.03,"amplitude":0.019599,"preClose":60.2082,"low":59.85,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61,"committee":0.444251,"eps":3.057033,"divideRate":0.024972,"volume":26376,"delay":0,"ttmEps":3.057033,"open":60.28,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":61.8701,"twentyDayClose":61.1284,"sixtyDayClose":59.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673085570","title":"Guardant Health reports COSMOS study published in Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085570?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:30","pubTimestamp":1791214209,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results fro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EKG","GH","GNMX","GNOM","FFOX","BK4585","BK4551","BK4535","BK4196","HELX","LU0889565916.HKD","LFSC","LU0320765992.SGD","LU0109394709.USD","BK4588","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085807","title":"Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085807?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:27","pubTimestamp":1791214069,"startTime":"0","endTime":"0","summary":"Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrencesGuardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5cqdWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GH","LU0109394709.USD","EKG","GNMX","BK4585","GNOM","HELX","GDOC","LU0320765992.SGD","LU0889565916.HKD","BK4588","FFOX","LFSC","PTH","BK4196","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702723","title":"Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:14","pubTimestamp":1791202453,"startTime":"0","endTime":"0","summary":"Revolution Medicines starts Phase 3 trial of RASONQUE-zoldonrasib combo in first-line metastatic RAS G12D pancreatic cancerRevolution Medicines began dosing patients in a global Phase 3 trial testing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1LgfsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BQXX3D17.EUR","PTH","LU2095319765.USD","BK4588","IE00B4R5TH58.HKD","LU0314104364.USD","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BFTCPJ56.SGD","SG9999014013.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00B64PRP62.GBP","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BQXX3C00.GBP","BK4139","CANC","IE00BN0W2T93.GBP","NDAQ","LU2210149790.SGD","SG9999014039.USD","IDNA","RVMD","IE00BN0W2W23.USD","LU2210150020.SGD","IE0002141913.USD","SG9999014005.SGD","BK4112","IE0009354923.USD","IE00BKPKM429.USD","BK4585","BBH","LU0109394709.USD","IE0009355771.USD","SG9999014021.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702923","title":"Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702923?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7YHCFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","RVMD","PTH","BBH","IE0009355771.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B4R5TH58.HKD","IDNA","CANC","IE0009354923.USD","IE00BJJMRZ35.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702771","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702771?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","PTH","BK4551","GDOC","BK4218","PK","BK4585","GNMX","BK4181","BK4183","BK4539","FFOX","LU0889565916.HKD","GNOM","LU0320765992.SGD","KBWY","BK4007","LU0109394709.USD","BK4139","BK4535","ENDO","BK4196","EKG","HELX","LENZ","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709483","title":"Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709483?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:11","pubTimestamp":1791195096,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765992.SGD","PTH","RVMD","IE00BJJMRZ35.SGD","IDNA","IE00BJT1NW94.SGD","CANC","BBH","LU0109394709.USD","IE0009354923.USD","LU0889565916.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672263897","title":"Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity","url":"https://stock-news.laohu8.com/highlight/detail?id=2672263897","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672263897?lang=en_us&edition=fundamental","pubTime":"2026-10-03 21:22","pubTimestamp":1791033739,"startTime":"0","endTime":"0","summary":"If you had paused on 2 October 2025, looking at BrightSpring Health Services as analysts argued over margins, regulation, and aging demographics, the choice did not look simple. For BrightSpring Health Services shareholders, the return over the past year was 112.4%, including dividends. That outcome is now fixed. The real question is what early buyers were weighing back then about specialty pharmacy momentum, leverage, and government reimbursement risk before any of the later earnings...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2324357040.USD","PTH","LU2468319806.SGD","BK4196","LU2089984988.USD","BTSG","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672419217","title":"Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2672419217","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672419217?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:38","pubTimestamp":1790977094,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000Roivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares at a weighted-av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6N8y8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4585","BK4588","PTH","BK4139","IMVT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672476771","title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672476771","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672476771?lang=en_us&edition=fundamental","pubTime":"2026-10-02 06:00","pubTimestamp":1790892038,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Development Officer Alan B. Sandler disposes of USD 1,264,082 in common sharesRevolution Medicines Chief Development Officer Alan B. Sandler exercised stock options for 6,00","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL9BczFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","BK4139","BBH","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009354923.USD","IE00B2B36J28.USD","CANC","PTH","LU0320765992.SGD","RVMD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4196","GDOC","HELX","BK4588","GNMX","LU0109394709.USD","FFOX","LFSC","PTH","GH","BK4585","LU0889565916.HKD","LU0320765992.SGD","GNOM","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672475403","title":"BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672475403","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672475403?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:05","pubTimestamp":1790856336,"startTime":"0","endTime":"0","summary":"BrightSpring Health updates financial calendar for third-quarter 2026 results release and callBrightSpring Health Services schedules its third-quarter 2026 earnings release for Oct. 30, 2026.Earnings ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLs3mT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","PTH","NDAQ","BTSG","SG9999014005.SGD","BCDF","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4588","BK4112","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2468319806.SGD","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","BK4585","LU2095319765.USD","LU2089984988.USD","PSCH","BK4196","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751724","title":"Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751724","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751724?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:32","pubTimestamp":1790854322,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma buys back 46,000,000 shares for US$ 230 million in Dutch auction tender offerArbutus completed a modified Dutch auction tender offer, repurchasing 46,000,000 common shares for cancel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Zy8XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BCDF","PTH","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","ROIV","IE00BQXX3C00.GBP","BK4007","BK4139","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","ABUS","BK4588","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671093162","title":"Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671093162","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671093162?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:30","pubTimestamp":1790767828,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma repurchases 46,000,000 shares for USD 230 million in modified Dutch auction tender offerArbutus Biopharma expects to repurchase 46,000,000 common shares for cancellation in a modifie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8GWhnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014021.USD","BK4588","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","ABUS","ROIV","PTH","LU0314104364.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","BCDF","IE00BKPKM429.USD","IE00BQXX3C00.GBP","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671117244","title":"New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2671117244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671117244?lang=en_us&edition=fundamental","pubTime":"2026-09-30 02:43","pubTimestamp":1790707417,"startTime":"0","endTime":"0","summary":"How hot are biotech stocks? One of the bellwethers for the industry, the iShares Biotechnology ETF ($IBB) (left chart), has gained over 24% year to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","NVIB","XLK","PTH","BK4550","BK4585","BIOY","FBT","FDN","JHMH","XBIX","IBB","RXL","BIS","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210199","title":"Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210199?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:40","pubTimestamp":1790689233,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Ax...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-clearpoint-neuro-clpt-and-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-clearpoint-neuro-clpt-and-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2324357040.USD","BK4532","AXSM","NVOH","BK4599","THNR","PPH","IE00BKVL7J92.USD","BK4007","CLPT","LU1093756325.SGD","IE00BZ1G4Q59.USD","OZEM","LU0154236417.USD","NVOC","BK4585","BK4082","BK4588","LU1093756168.USD","BK4505","NVOX","NVO","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671921642","title":"Axsome Therapeutics, Inc. : Deutsche Bank Cuts Target Price to $267 from $280","url":"https://stock-news.laohu8.com/highlight/detail?id=2671921642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671921642?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:20","pubTimestamp":1790680843,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0RM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","LU2324357040.USD","BK4585","BK4505","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101970069","title":"Shenzhen Lifotronic Technology Secures Medical Device Registration Certificate for Photon Therapeutic Apparatus","url":"https://stock-news.laohu8.com/highlight/detail?id=1101970069","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101970069?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:29","pubTimestamp":1790674165,"startTime":"0","endTime":"0","summary":"Shenzhen Lifotronic Technology Co.,Ltd. (688389.SH) has announced that its controlling subsidiary, Chongqing Lifotronic Biotechnology Co., Ltd., recently received the Medical Device Registration...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","LNGR","HART","RSPH","BK1100","GDOC","BK1574","MEDX","159883","LGHT","BK0251","IEIH","BK1583","PTH","09996","688389","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671013268","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2671013268","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671013268?lang=en_us&edition=fundamental","pubTime":"2026-09-29 06:00","pubTimestamp":1790632843,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sells USD 743,436 in common sharesRevolution Medicines Chief Global Commercialization Officer Anthony Mancini reported sales","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLcdFr5m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IDNA","IE0009355771.USD","LU0109394709.USD","IE00B2B36J28.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","CANC","PTH","BK4139","BBH","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670259517","title":"Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670259517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670259517?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:58","pubTimestamp":1790611096,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) is expected to have a \"strong\" launch for its Rasonque drug in second-line pancreatic ductal adenocarcinoma patients, and in some first-line patients as well, UBS Securitie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD","IDNA","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD","PTH","CANC","BBH","IE00BFTCPJ56.SGD","IE0009354923.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132272624","title":"Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together","url":"https://stock-news.laohu8.com/highlight/detail?id=1132272624","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132272624?lang=en_us&edition=fundamental","pubTime":"2026-09-28 13:22","pubTimestamp":1790572929,"startTime":"0","endTime":"0","summary":"On the first trading day after the Mid-Autumn Festival (September 28), A-shares underwent a deep correction, with the Shanghai Composite Index falling nearly 2% at one point. Pharmaceutical assets...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["562050","BK1100","159883","BK0028","BK1583","BK0239","GDOC","BK0188","BK1161","000513","HART","BK1574","BK1515","LNGR","MEDX","AGNG","RSPH","LGHT","MDEV","PTH","09939","09996","159938","BK0187","IEIH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}